Pre-made Lanadelumab benchmark antibody ( Whole mAb, anti-KLKB1 therapeutic antibody, Anti-KLK3/PKK/PKKD/PPK Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lanadelumab biosimilar, Whole mAb, Anti-KLKB1 Antibody: Anti-KLK3/PKK/PKKD/PPK therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lanadelumab (INN; trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa)that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in patients with hereditary angioedema. Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks. Takhzyro is the first treatment for hereditary angioedema (HEA) prevention made by using cells within a lab, not human plasma.[8] The US Food and Drug Administration approved the use of lanadelumab on 23 August 2018 for patients that are 12 years and older and suffering from either type I or type II hereditary angioedema (HEA). Administration of the medication is done through 1 subcutaneous injection at a dose of 300 milligrams every 2 weeks (every 4-week dosing can be considered in specific patients).